The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens

[1] Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30

[2] Miller KD(2011)Revolution in lung cancer: new challenges for the surgical pathologist Arch Pathol Lab Med 135 110-116

[3] Jemal A(2012)Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC) Crit Rev Oncol Hematol 81 49-57

[4] Cagle PT(2015)Targeted therapy for non-small cell lung cancer: current standards and the promise of the future Transl Lung Cancer Res 4 36-54

[5] Allen TC(2015)Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors Drug Resist Updat 20 12-28

[6] Dacic S(2015)Molecular histology of lung cancer: from targets to treatments Cancer Treat Rev 41 361-375

[7] Beasley MB(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388

[8] Borczuk AC(2010)Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat Rev Clin Oncol 7 493-507

[9] Chirieac LR(2013)Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19 2240-2247

[10] Laucirica R(2014)EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Am J Cancer Res 4 411-435

[1] Siegel RL(2018)Cancer statistics, 2018 CA Cancer J Clin 68 7-30

[2] Miller KD(2011)Revolution in lung cancer: new challenges for the surgical pathologist Arch Pathol Lab Med 135 110-116

[3] Jemal A(2012)Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC) Crit Rev Oncol Hematol 81 49-57

[4] Cagle PT(2015)Targeted therapy for non-small cell lung cancer: current standards and the promise of the future Transl Lung Cancer Res 4 36-54

[5] Allen TC(2015)Fighting cancer drug resistance: opportunities and challenges for mutation-specific EGFR inhibitors Drug Resist Updat 20 12-28

[6] Dacic S(2015)Molecular histology of lung cancer: from targets to treatments Cancer Treat Rev 41 361-375

[7] Beasley MB(2010)Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2380-2388

[8] Borczuk AC(2010)Understanding resistance to EGFR inhibitors-impact on future treatment strategies Nat Rev Clin Oncol 7 493-507

[9] Chirieac LR(2013)Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers Clin Cancer Res 19 2240-2247

[10] Laucirica R(2014)EGFR-TKI resistance in NSCLC patients: mechanisms and strategies Am J Cancer Res 4 411-435